Beyond the Biospecimen
Welcome to Sanguine’s LinkedIn Newsletter - Beyond the Biospecimen. In this newsletter we highlight a few topics each month about biospecimens for research and the data associated with the sample.
?Time between collection and processing of biospecimens can be critical
Last year, Yi et al.? highlighted the importance of minimizing the time between sample collection and PBMC processing, as they observed variability in downstream assays over time. One key advantage of having an OnSite blood donation program is the ability to mitigate this issue. With a Sanguine-managed OnSite program, researchers can access fresh, healthy blood samples almost immediately after collection. We handle everything—from regulatory compliance and donor recruitment within your organization to performing the collections—ensuring speed and efficiency in your research process.
Watch this video to learn more.
GMP Leukopaks Coming Soon to Sanguine
Sanguine is preparing to launch healthy GMP-grade leukopaks, delivering high-quality immune cell collections that adhere to rigorous Good Manufacturing Practice (GMP) standards. These leukopaks will provide a consistent and reliable source of cells, complemented by comprehensive donor data from reserved donors. Here are just a few of the deliverables with your GMP leukopak:
? Donor demographics including height, weight, age, ethnicity, and medications
? 21 CFR 1271 Compliant Panel of infectious disease testing?
? HLA-typing Class I/II
领英推è
Why ISO Certifications Matter for Quality, Data Security and Privacy
In today’s world, data security and privacy are more important than ever. At Sanguine, we are proud to have recently achieved three ISO certifications, ensuring that the highest standards of quality, information security and privacy are met. Our latest blog breaks down why these certifications are crucial for safeguarding sensitive data and maintaining trust with our clients. Explore how these global standards reinforce our commitment to protecting your valuable information.
Read more to see what sets us apart!
Need healthy or disease-state PBMCs, serum, or plasma fast?
Although Sanguine was founded on our in-home collections for prospective studies, we also have inventory ready to share from our freezer to yours. We have over 50 diagnosed conditions, as well as biospecimens from healthy donors, in our freezers ready-to-ship to you. Here are just a few of the disease-state samples we have available:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pemphigus
- Sjogren's Syndrome
Contact us to learn about our special end of the year pricing on our inventory of healthy PBMCs or check-out our inventory list.?
Biospecimens in action?
Below we highlight a few recent publications where biospecimens collected by Sanguine were used. We are grateful to our 70,000 plus donor network who are helping to accelerate biomedical research.?
?? Shim et al. from Genentech explored the impact of measuring antibodies in samples over time in their study titled "Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood." The team used blood samples collected by Sanguine from donors with multiple sclerosis and found that pharmacokinetic (PK) measurements of ocrelizumab were not affected by delayed centrifugation of whole blood. This finding suggests that in-home collections may be suitable for certain clinical trials (depending upon the sample type needed), reducing the burden on patients and their caregivers.
??Fang et al. from Takeda investigates miRNA signatures in “Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations.†The study finds that both methods yield distinct miRNA profiles but consistently associate these miRNAs with angiogenesis pathways, suggesting their potential as biomarkers for early diagnosis and treatment monitoring of Fabry disease.